The phase III, randomized, double-blind, placebo-controlled KEYNOTE-811 study of pembrolizumab plus trastuzumab and chemotherapy for HER2+metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma

Rha, S. Y., Kawazoe, A., Bai, Y., Xu, J., Lonardi, S., Metges, J-P., Yanez Weber, P. E., Wyrwicz, L. S., Shen, L., Ostapenko, Y. V., Bilici, M., Chung, H. C., Shitara, K., Qin, S., van Cutsem, E., Tabernero, J., Li, K., Shih, C-S., Bhagia, P., Janjigian, Y. Y.